Overview

Ultra-high-sensitivity EGFR T790M detection is a molecular diagnostic service used to guide therapy in EGFR-driven non-small cell lung cancer. Because the result directly influences whether a patient moves to a next-line targeted agent, the analytical and regulatory quality of the test carries as much weight as the clinical question. Procurement and laboratory managers evaluating such assays should assess accreditation, validation evidence, and reporting discipline before adoption.

Laboratory Accreditation and Quality Systems

Reputable molecular testing is performed under recognized quality frameworks. In the United States, clinical laboratories operate under CLIA, while CAP accreditation adds peer-reviewed inspection of laboratory processes. In many other regions, ISO 15189 sets the standard for medical laboratories. These frameworks govern personnel competency, equipment calibration, internal quality control, and participation in external proficiency testing - the mechanisms that keep a low-frequency mutation like T790M detectable and reportable over time.

For an ultra-high-sensitivity assay, buyers should request documented limit of detection and evidence that the method was validated on both tissue and plasma inputs where relevant. A vendor that cannot state its analytical sensitivity should be treated with caution regardless of turnaround claims.

Sample Integrity and Reporting Integrity

Pre-analytical handling strongly affects T790M detection. Plasma samples must be processed within the recommended window to preserve circulating tumor DNA, and tissue must be collected and stored to avoid nucleic-acid degradation. Laboratories should report not only the mutation call but also the specimen type, the methodology, and the limit of detection, because a negative plasma result has different meaning from a negative tissue result.

Chain-of-custody and data security are additional regulatory touchpoints, particularly when tests cross borders or feed into multinational treatment programs. Clear, auditable reporting protects both the patient and the institution procuring the service.

FAQ

Q: Which accreditations matter for an EGFR T790M test? A: CLIA and CAP in the United States, and ISO 15189 in many other regions, are the principal frameworks governing molecular laboratory quality.

Q: Why is limit of detection important for T790M? A: T790M can appear at very low abundance, especially in blood, so the stated analytical sensitivity determines whether a true low-level mutation is caught.

Q: Should tissue and plasma results be reported differently? A: Yes. Accredited labs state specimen type and method, since a negative plasma result may warrant tissue confirmation while a negative tissue result is more definitive.

Q: What pre-analytical factors affect test quality? A: Timely plasma processing to preserve circulating tumor DNA and proper tissue collection and storage are the main variables that protect result reliability.